ArticleAmerican journal of translational research2024
Clinical efficacy and safety of Tinidazole combined with minocycline in treating peri-implantitis.
Article in American journal of translational research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the effects of tinidazole (TNZ) combined with minocycline (MINO) on therapeutic effectiveness, bone resorption, and inflammation in peri-implantitis (PI).
methodsThis retrospective study included 96 PI patients admitted between January 2023 and February 2024. Patients were divided into a control group (n = 46) treated with MINO and a research group (n = 50) treated with TNZ plus MINO. Therapeutic effectiveness, post-treatment plaque biofilm activity at different depths, periodontal indexes [modified plaque index (mPLI), modified sulcus bleeding index (mSBI), probing depth (PD), and peri-implant marginal bone loss (MBL)], inflammatory markers [interleukin (IL)-1β, IL-8, and matrix metalloproteinase-8 (MMP-8)], pain scores [Visual Analogue Scale (VAS)], quality of life [Short Form 36 Item Health Survey (SF-36)], and adverse reactions were compared. Univariate and multivariate analyses were performed to identify factors influencing therapeutic effectiveness.
resultsThe research group demonstrated significantly higher therapeutic effectiveness and lower mPLI, mSBI, PD, MBL, and plaque biofilm activity at different depths compared to the control group (all P < 0.05). Additionally, greater reductions in VAS scores and increases in SF-36 scores were observed in the research group post-treatment (both P < 0.05). No severe adverse reactions occurred in either group, and the incidence of adverse events showed no significant inter-group difference (P > 0.05). Univariate analysis revealed that disease duration, history of periodontitis, smoking, and treatment modality were significantly associated with therapeutic effectiveness (all P < 0.05). Multivariate analysis identified smoking as an independent factor influencing treatment outcome.
conclusionsTNZ combined with MINO is a highly effective and safe treatment for PI. This combination reduces plaque, alleviates periodontitis, and improves patients' quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.